Effect of aspirin and antiplatelet drugs on the outcome of the fecal immunochemical test

Mayo Clinic Proceedings

Volumn 88, Issue 7, 2013, Pages 683-689

  Bujanda, Luis ^a   Lanas, Ángel ^c   Quintero, Enrique ^d   Castells, Antoni ^e   Sarasqueta, Cristina ^b   Cubiella, Joaquín ^g   Hernandez, Vicent ^h   Morillas, Juan D ⁱ   Perez Fernández, Teresa ⁱ   Salas, Dolores ^j   Andreu, Montserrat ^f   Carballo, Fernando ^k   Bessa, Xavier ^f   Cosme, Angel ^a   Jover, Rodrigo ^l  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g Unidad de Enfermedades Infecciosas   (Spain)

^h UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^j Programa de Cribado de Cáncer Colorrectal Dirección General de Salud Pública Conselleria de Sanitat   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^l HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADULT; ADVANCED CANCER; AGED; CANCER SCREENING; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FECAL IMMUNOCHEMICAL TEST; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PREDICTIVE VALUE;

EID: 84880216244     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.04.016     Document Type: Conference Paper

References (30)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
2. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570-1595.
3. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occultblood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343(22):1603-1607.
4. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am J Gastroenterol. 2008;103(6):1541-1549.
5. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010; 375(9726):1624-1633.
6. Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ. Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med. 2010;7(12):1-13.
7. Sawhney MS, McDougall H, Nelson DB, Bond JH. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci. 2010; 55(6):1637-1642.
8. Mandelli G, Radaelli F, Paggi S, et al. Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: results from a nested in a cohort case-control study. Eur J Gastroenterol Hepatol. 2011;23(4): 323-326.
9. Levi Z, Rozen P, Hazazi R, et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs and anticoagulants. Am J Gastroenterol. 2009;104(4): 933-938.
10. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical test in colorectal cancer screening. N Engl J Med. 2012;366(8):697-706.
11. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005;100(11):2519-2525.
12. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420-1425.
13. Jover R, Herráiz M, Alarcón O, et al Spanish Society of Gastroenterology; Spanish Society of Gastrointestinal Endoscopy Working Group. Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy. 2012;44(4):444-451.
14. Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Arch Intern Med. 1999;159(12):1322-1328.
15. Sharma VK, Corder FA, Fancher J, Howden CW. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test. Am J Gastroenterol. 2000;95(12):3629-3632.
16. Brenner H, Tao S, Haug U. Low-dose aspirin use and performance of immunochemical fecal occult blood test. JAMA. 2010;304(22):2513-2520.
17. Kahi CJ, Rex DK, Imperiale TF. Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. Gastroenterology. 2008;135(2):380-399.
18. Park DI, Ryu S, Kim Y, et al. Comparison guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010;105(9):2017- 2025.
19. Hernández V, Cubiella J, Gónzalez-Mao C, et al. Diagnostic accuracy of the fecal immunochemical test (FIT) to screen for colorectal cancer and advanced neoplasia in individuals with intermediate risk. Gastroenterol Hepatol. 2012;35(3):144-145.
20. Nakama H, Kamijo N, Fujimori K, et al. Diagnostic accuracy of immunochemical faecal occult blood test for gastric cancer. J Med Screen. 1996;3(3):113-114.
21. Nakama H, Kamijo N, Fattah AS, Zhang B. Immunologic detection of fecal occult blood from upper digestive tract diseases. Hepatogastroenterology. 1998;45(21):752-754.
22. Nakama H, Zhang B. Immunochemical fecal occult blood test is inadequate for screening test of stomach cancer. Dig Dis Sci. 2000;45(11):2195-2198.
23. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in screening population. Gastroenterology. 2008;135(1):82-90.
24. Allison JE, Tekawa IS, Ransom LJ, et al. A comparison of fecal occult blood tests for colorectal cancer screening. N Engl J Med. 1996;334(3):155-159.
25. Blacker DJ, Wijdicks EF, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology. 2003;61(7):964-968.
26. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: joint guidelines from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570-1595.
27. Lanas A, García Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006; 55(12):1731-1738.
28. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7): 494-502.
29. Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients: randomised, double-blind, placebo-controlled trial. Lancet. 2004; 364(9431):331-337.
30. Chan AO, Jim MH, Lam KF, et al. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA. 2007;298(12):1412-1419. Recerca Saúde Pública